TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11955393
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg consecutive mitomycin C
Study: 6750929
Drug: Alpha- and
Normalized name: Alpha- and beta-trypsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha- and betamimetics, cholinesterase inhibitors
Study: 30732459
Drug: Program A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program A (two months without acute analgesics or migraine medications)
Study: 30732459
Drug: Program B
Normalized name: ZINC OXIDE 3 g in 100 g / OCTOCRYLENE 6 g in 100 g / ENSULIZOLE 4 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g TOPICAL CREAM [NECK DECOLLETE HAND ARM DAY REPARATIVE HYDRATION RESCUE AND REPROGRAM BROAD SPECTRUM SPF 35 SUNSCREEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program B (two months with acute medications restricted to two days/week)
Study: 21627398
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple drug therapy (omeprazole, clarithromycin, and amoxicillin for 10 days)
Study: 15211234
Drug: Pristinamycin 3
Normalized name: pristinamycin
DrugBank: Pristinamycin (DB13704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pristinamycin 3 G daily for 4 days
Study: 15211234
Drug: Co-amoxiclav 2
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 2 G daily for 8 days
Study: 11683127
Drug: Lanzor (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanzor (reference formulation)
Study: 8701855
Drug: Flosequinan 100
Normalized name: flosequinan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan 100 mg once daily
Study: 8701855
Drug: Flosequinan 75
Normalized name: flosequinan 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan 75 mg twice daily
Study: 1876437
Drug: ICS 205-930
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS 205-930 (15 mg daily)
Study: 1876437
Drug: ICS 205-930
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS 205-930 (25 mg daily)
Study: 1876437
Drug: ICS 205-930
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS 205-930 (50 mg daily)
Study: 22416798
Drug: darunavir/ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors (triple therapy)
Study: 4006483
Drug: Beta-Blocker Heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-Blocker Heart Attack Trial (BHAT)
Study: 28980306
Drug: 50% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% oxygen inhalation
Study: 16962720
Drug: Air inhalation
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air inhalation
Study: 25500684
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium valproate
Study: 27878767
Drug: Intravenous phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phenobarbital
Study: 19473858
Drug: articaine 20mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: articaine 20mg/ml
Study: 19473858
Drug: articaine 40mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: articaine 40mg/ml
Study: 11898704
Drug: Vaginal solution
Normalized name: VAGINAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal solution 40 mg of phentolamine
Study: 11898704
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet 40 mg of phentolamine
Study: 9895068
Drug: Sympathectomy (lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sympathectomy (lidocaine injection into the brachial plexus)
Study: 9895068
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution injection (placebo)
Study: 7297411
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 or 100 mg)
Study: 16162624
Drug: No ACE
Normalized name: Amino Acetic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACE inhibitors
Study: 11044647
Drug: Method of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method of treatment allocation
Study: 8471439
Drug: Cooper type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooper type regimens without doxorubicin (replaced by one or more compounds)
Study: 26669628
Drug: Ospemifene 60
Normalized name: ospemifene 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ospemifene 60 mg/day
Study: 29105211
Drug: Parent-focused family-based
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-focused family-based treatment (PFT)
Study: 20568829
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg/kg alone
Study: 20568829
Drug: Sugammadex 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 32 mg/kg with rocuronium 1.2 mg/kg
Study: 20568829
Drug: Sugammadex 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 32 mg/kg with vecuronium 0.1 mg/kg
Study: 18334007
Drug: Weekly topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly topotecan (4 mg/m(2))
Study: 8282360
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fosinopril plus 12.5 mg hydrochlorothiazide
Study: 10856268
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fosinopril
Study: 3534801
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg hydrochlorothiazide
Study: 2567740
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg bid
Study: 31698825
Drug: Pemafibrate 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate 0.1 mg/day
Study: 31698825
Drug: Pemafibrate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate 0.2 mg/day
Study: 21901116
Drug: HealthyDiet group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HealthyDiet group (whole grain and low postprandial insulin response grain products, fatty fish three times a week, and bilberries three portions per day)
Study: 12611748
Drug: HL 2
Normalized name: SODIUM CHLORIDE 0.9% INHL 2.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL 2 mg-3 mg/day (standard dose)
Study: 11317829
Drug: Oral gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gatifloxacin 400 mg once daily
Study: 9174486
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g n-3 ethyl esters three times a day for 2 months
Study: 9174486
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g n-3 ethyl esters twice a day for 4 months
Study: 21169815
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg 12 hours before PCI, plus 40 mg preprocedure)
Study: 16910475
Drug: Sevoflurane with
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane with 0.6 mg x kg(‐1) Org 9426
Study: 16910475
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with 0.6 mg x kg(‐1) Org 9426
Study: 16910475
Drug: Sevoflurane with
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane with 0.9 mg x kg(‐1) Org 9426
Study: 16910475
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with 0.9 mg x kg(‐1) Org 9426
Study: 16910475
Drug: Sevoflurane (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane (both doses)
Study: 16910475
Drug: Propofol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (both doses)
Study: 16910475
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg x kg(‐1) Org 9426
Study: 15479777
Drug: High-dose (>30
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (>30 mg/kg) rectally administered acetaminophen
Study: 9134651
Drug: PAI-1 activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAI-1 activity in stroke patients (n = 245) at presentation (11.6 U/ml) and after three months (11.8 U/ml)
Study: 31400231
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg IgPro20
Study: 31400231
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg IgPro20
Study: 30058061
Drug: Intramuscular 8mg
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 8mg lornoxicam (Group 1, n=27)
Study: 30058061
Drug: Intravenous 8mg
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 8mg lornoxicam (Group 2, n=24)
Study: 19398614
Drug: Immediate intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate intervention consisting of eighteen 30‐minute lessons delivered twice weekly for 9 weeks, focusing on teaching critical emergent literacy skills within small groups.
Study: 10397521
Drug: 2% minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% minocycline ointment
Study: 2426069
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (COF regimen: Vincristine 1 mg, cyclophosphamide 600 mg, 5-fluorouracil 500 mg IV on days 1 and 8, with or without Pingyangmycin 10 mg IM on days 1, 3, 6, and 8)
Study: 30673004
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise therapy with a single supervised session (Group A)
Study: 23150095
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (observation)
Study: 17443645
Drug: Oral bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral bicalutamide
Study: 15886663
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic calf and foot compression (IPCFC) applied for 1 hour twice daily in the sitting position, along with daily exercise.
Study: 12562884
Drug: Daily supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supervised brushing with fluoride toothpaste
Study: 11084786
Drug: Adenosine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (3 mg bolus) with K(+)-enriched cardioplegia
Study: 10201459
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg twice daily
Study: 6628792
Drug: 2.0% DNCB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% DNCB ointment for 2 days followed by 0.05% DNCB ointment daily (group I)
Study: 6628792
Drug: 0.05% DNCB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% DNCB preparation only (group II)
Study: 20464985
Drug: Intervention treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention treatment group (systemic patient management including patient education, regular telephone interviews, physician-patient communication)
Study: 20464985
Drug: General treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: General treatment group (normal clinical procedure)
Study: 20464985
Drug: Intervention treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention treatment group
Study: 17013594
Drug: Increasing contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing contrast agent dosage
Study: 15653005
Drug: Low-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormone replacement therapy with 0.3mg of conjugated equine estrogens (CE) and 2.5 mg MPA (CE + MPA)
Study: 15653005
Drug: Low-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormone replacement therapy with 0.3mg of conjugated equine estrogens (CE) and 100 mg natural micronized progesterone (CE + P)
Study: 7542336
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (0, 0.5, 2, 8, 16 and 32 mg)
Study: 7542336
Drug: p.o. methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. methadone (3.75, 15 and 60 mg)
Study: 7542336
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of methadone
Study: 2221770
Drug: Bupivacaine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.6 ml/kg, 0.25% = 1.5 mg/kg) injected intradermally into the wound during general anaesthesia
Study: 1389845
Drug: Suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1 mg kg‐1
Study: 26111150
Drug: Ramipril (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (usual treatment group)
Study: 17325084
Drug: No doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No doxycycline treatment (Control)
Study: 28581335
Drug: Daily diary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily diary writing
Study: 8991468
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg induction, 15-20 mg/kg x h maintenance with 30% O2 in air)
Study: 8991468
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg induction, 10-15 mg/kg x h maintenance with N2O)
Study: 14551368
Drug: Bicarbonate concentration
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate concentration 32 mmol/l (modality A)
Study: 10843171
Drug: Risedronate 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 2.5 mg/day
Study: 10841169
Drug: Combined risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined risedronate treatment groups
Study: 2863596
Drug: Thrombolysis (intracoronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis (intracoronary streptokinase up to 250,000 U, with some receiving intravenous streptokinase 500,000 U)
Study: 26429652
Drug: Brazil nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nuts (15 to 30 g, 3 days/week)
Study: 18257349
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus ear point tapping and pressing therapy
Study: 7797783
Drug: Routine cleaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine cleaning measures including daily cleaning of smooth floors, weekly laundering of sheets, and monthly cleaning of soft toys; use of synthetic mattress covers.
Study: 22151936
Drug: 4% hydroquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% hydroquinone cream
Study: 23649578
Drug: 0.4% Stannous
Normalized name: Stanimax 0.4% Stannous Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% Stannous Fluoride Gel
Study: 21735693
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy (1700 mg daily for 6 months)
Study: 20104753
Drug: Ganciclovir (GCV)
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir (GCV) 5-10 mg/(kg x d) for 5 days
Study: 16916184
Drug: Inhaled anaesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anaesthetics
Study: 12625640
Drug: Intramuscular EMG-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular EMG-controlled NMES
Study: 8887920
Drug: argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: argon laser treatment (ALT)
Study: 8887920
Drug: double-frequency Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: double-frequency Nd:YAG laser treatment (NdLT)
Study: 3517643
Drug: Penicillamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillamine (10 mg/kg/day)
Study: 3517643
Drug: Hydroxychloroquine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (6 mg/kg/day)
Study: 25440796
Drug: Alirocumab (75-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75-150 mg biweekly injections)
Study: 29604186
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching injections)
Study: 22753208
Drug: Antihypertensive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive agents for approximately 12 months
Study: 18310581
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy plus treatment as usual
Study: 11168249
Drug: Maxillary long-bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary long-bar implant overdentures with palatal coverage
Study: 31888944
Drug: Free and
Normalized name: Free and Clear
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free and easily accessible medicines (intervention)
Study: 26254237
Drug: GP care
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP care with additional exercise therapy (maximum of 12 sessions in the first 3 months and three booster sessions thereafter)
Study: 24462034
Drug: Standard medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medications
Study: 22730862
Drug: Timely bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timely bolus insulin (0.2 iu/kg at aortic cannulation, additional 0.1 iu/kg for BG > 10.0 mmol/L)
Study: 22730862
Drug: Timely bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timely bolus insulin
Study: 3653498
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg three times a day)
Study: 9045106
Drug: Inactivated Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Lactobacillus acidophilus with antibiotic therapy for extraintestinal pathologies
Study: 6733040
Drug: Short-contact dithranol
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-contact dithranol therapy
Study: 30879707
Drug: Weekly low-grade
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly low-grade (I-II) Kaltenborn manual mobilization of the hands
Study: 30006117
Drug: Single-implant mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-implant mandibular overdentures (SIMO)
Study: 26828801
Drug: Paraspinous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paraspinous lidocaine injection, analgesics, and exercises (LID-INJ)
Study: 26828801
Drug: Sham paraspinous
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham paraspinous lidocaine injection, analgesics, and exercises (SH-INJ)
Study: 26828801
Drug: Analgesics and
Normalized name: Analgesics and anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics and exercises (STD-TTR)
Study: 24249680
Drug: Pharmacist-initiated multidisciplinary
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmacist-initiated multidisciplinary strategy (education, pain medication management, physiotherapy-guided exercise, communication with primary care physician)
Study: 23113511
Drug: Non-thermal, non-ablative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-thermal, non-ablative CO(2) laser therapy (NACLT)
Study: 15712100
Drug: Levofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (750 mg iv q24h)
Study: 15712100
Drug: Imipenem-cilastatin (500-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (500-1000 mg iv q6-8h)
Study: 7598139
Drug: Step-One diet
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-One diet plus continuous combined hormone-replacement therapy (conjugated estrogens 0.625 mg/d plus medroxyprogesterone 2.5 mg/d)
Study: 2222986
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day of baclofen
Study: 26553894
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention including academic detailing, web-based treatment algorithms, and tailored patient information leaflets
Study: 21906314
Drug: Chlorella-derived multicomponent
Normalized name: Chlorella emersonii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella-derived multicomponent supplement (30 tablets per day for 4 weeks)
Study: 21906314
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 tablets per day for 4 weeks)
Study: 12649401
Drug: Chimeric anti-TNFalpha
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric anti-TNFalpha antibodies (3 mg/kg, bimonthly i.v.)
Study: 8055999
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide mononitrate
Study: 2648642
Drug: Ranitidine treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine treatment, 150 mg twice daily for four weeks
Study: 25138784
Drug: Gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600 mg)
Study: 25987833
Drug: Generic clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic clopidogrel bisulfate 75 mg film‐coated tablets
Study: 25987833
Drug: Plavix® clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plavix® clopidogrel bisulfate 75 mg film‐coated tablets
Study: 17598007
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) - 5,000 IU iv bolus followed by 450 IU/kg/24 h for 72 hours (n = 7)
Study: 17598007
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH; dalteparin) - 200 IU/kg sc once daily for 72 hours (n = 8)
Study: 17598007
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH; dalteparin) - 100 IU/kg sc once (n = 8)
Study: 11531036
Drug: Reparil‐Gel N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reparil‐Gel N (n = 32)
Study: 11531036
Drug: Reparil‐Gel (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reparil‐Gel (n = 31)
Study: 11531036
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (n = 31)
Study: 1460184
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (75 mg Zn/day)